Immune System, TBP Flashcards
Hypersensitivity reactions, type: IgE mediated
Type I
Hypersensitivity reactions: TH2 cells release this substance that stimulates eosinophils
IL-5
Hypersensitivity reactions: TH2 cells release this substance that activates IgE-producing b-cells
IL-4
Hypersensitivity reactions: IgE binds to what cells
Mast cells
Hypersensitivity reactions: Binding of antigen to IgE on mast cells result in
Mast cell degranulation and release of mediators
Type I hypersensitivity: Phases
Early and late
Type I hypersensitivity: Early phase occurs within
5-30 minutes
Type I hypersensitivity: Early phase is due to
Binding of antigen to IgE bound to mast cells and release of mediators
Type I hypersensitivity: Late phase occurs within
2-24 hours
Type I hypersensitivity: Late phase is characterized by
Infiltration of inflammatory cells and release of mediators by these cells
Type I hypersensitivity: Marker of anaphylaxis
Serum tryptase
Hypersensitivity reactions, type: Antibody-mediated
Type II
Type II hypersensitivity: Mechanisms (3)
1) Complement-dependent
2) Antibody-dependent cell-mediated cytotoxicity
3) Antibody-mediated cellular dysfunction
Type II hypersensitivity mechanism: Cell types that bear receptors for Fc of IgG mediate removal of antigen
Antibody-dependent cell-mediated cytotoxicity
Type II hypersensitivity mechanism: Antibodies themselves affect function of antigen
Antibody-mediated cellular dysfunction
Hypersensitivity reactions, type: Immune complex-mediated
Type III
Hypersensitivity reactions, type: T cell-mediated
Type IV
Type IV hypersensitivity: Mechanisms
1) Delayed form in which CD4+ Th1 cells sensitised from previous exposure to antigen secretes IF-γ that activates macrophages
2) Cell-mediated form in which CD8+ cytotoxic T cells kill antigen-bearing cells
Type IV hypersensitivity: Mechanisms of cell-mediated cytotoxicity
1) Perforin-granzyme system
2) FAS-FAS ligand system
Type IV hypersensitivity, mechanism: Holes are produced in the plasma membrane of cells, allowing granzyme to enter cells and activate apoptosis
Perforin-granzyme system
Type IV hypersensitivity, mechanism: FAS ligamnd on T lymphocytes bind to FAS on target cells leading to apoptosis
FAS-FAS ligand system
Type of hypersensitivity: Bee sting
Type I
Type of hypersensitivity: Drug allergy
Type I
Type of hypersensitivity: Glomerulonephritis
Type II or III
Type of hypersensitivity: Transfusion reactions
Type II
Type of hypersensitivity: Tuberculin reaction
Type IV, CD4+-mediated
Type of hypersensitivity: Erythroblastosis fetalis
Type II
Type of hypersensitivity: Contrast media allergy
Type I
Type of hypersensitivity: Serum sickness
Type III
Type of hypersensitivity: Urticaria
Type I
Type of hypersensitivity: AIHA
Type II
Type of hypersensitivity: Graves disease
Type II
Type of hypersensitivity: Insect venoms
Type I
Type of hypersensitivity: Food allergy
Type I
Type of hypersensitivity: Myasthenia gravis
Type II
Type of hypersensitivity: Contact dermatitis
Type IV
Type of hypersensitivity: Transplant rejection
Type II and IV
Mechanisms of transplant rejection (2)
Cell-mediated or humoral mediated
Classifications of transplant rejection
1) Hyperacute
2) Acute
3) Chronic
Mechanisms by which cytotoxic T cells kill graft cells
1) Perforin-granzyme pathway
2) FAS-FAS ligand pathway
Forms of cellular rejection: Body recognises MHC molecules on surface of APCs in the graft
Direct
Forms of cellular rejection: Antigens of the graft are presented by recipient’s cells
Indirect
Classification of transplant rejection: Humoral reaction due to preformed antibodies to graft endothelium
Hyperacute rejection
Classification of transplant rejection: Cellular or humoral reaction
Acute rejection
Classification of transplant rejection: 4-6 months to years following graft
Chronic rejection
Classification of transplant rejection: Possibly due to indirect form of cellular rejection
Chronic rejection
Classification of transplant rejection: Minutes following transplantation
Hyperacute
Classification of transplant rejection: Days to months to years following transplantation
Acute
Classification of transplant rejection: Cyanosis of organ and mottled parenchyma
Hyperacute
Classification of transplant rejection: Endothelial injury, neutrophils in arterioles, infarcts of parenchyma
Hyperacute
Classification of transplant rejection: Vascular changes and interstitial fibrosis
Chronic
Classification of transplant rejection: Interstitial mononuclear infiltrate and edema
Acute
Classification of transplant rejection: Interstitial hemorrhage and endothelia’s (swollen endothelial cells)
Acute
Classification of transplant rejection: Interstitial mononuclear infiltrate and schema with loss of tissue
Chronic
Classification of transplant rejection: Necrotizing vasculitis, neutrophilic infiltrates, and infarcts of parenchyma
Acute
Classification of transplant rejection: Will respond to cyclosporine
Acute
Immune competent cells in the graft recognize antigens in the host
GVHD
GVHD: Occurs in transplant of what
1) Bone marrow transplant
2) Solid organ transplant when organ is rich in lymphocytes
3) Non-irradiated blood
GVHD: Forms
1) Acute
2) Chronic
GVHD, acute vs chronic: Days to weeks
Acute
GVHD, acute vs chronic: Skin rash
Acute
GVHD, acute vs chronic: Fibrosis of dermis and skin appendages
Chronic
GVHD, acute vs chronic: Cholestatic jaundice
Chronic
GVHD, acute vs chronic: Jaundice
Acute
GVHD, acute vs chronic: Esophageal strictures
Chronic
GVHD, acute vs chronic: Bloody diarrhea
Acute
GVHD, acute vs chronic: Immunodeficiency
Acute and chronic
GVHD: Infection commonly associated with immunodeficiency in GVHD
CMV pneumonia
General mechanism of autoimmune diseases
Loss of self-tolerance
Autoimmune diseases: Contributing factors to loss of self-tolerance (2)
1) Susceptibility genes such as HLA B27 in ankylosing spondyltitis
2) Infections that upregulate costimulatory proteins on APCs or molecular mimicry
Associated antibodies: SLE
1) Anti-dsDNA
2) Anti-Smith
Associated antibodies: Drug-induced lupus
Antihistone
Associated antibodies: RA
IgM vs Fc of Ig
Associated antibodies: Sjogren
Anti-SSA and anti-SSB